Sun Lingyi, Gai Yongkang, Li Zhonghan, Zhang Xiaohui, Li Jianchun, Ma Yongyong, Li Huiqiang, Barajas Ramon J, Zeng Dexing
Department of Radiology, University of Pittsburgh, Pittsburgh 15213, USA; Center of Radiochemistry Research, Knight Cardiovascular Institute, Oregon Health & Science University, Portland 97239, USA.
Department of Radiology, University of Pittsburgh, Pittsburgh 15213, USA.
Adv Ther (Weinh). 2021 Oct;4(10). doi: 10.1002/adtp.202100110. Epub 2021 Aug 21.
PET imaging has become an important diagnostic tool in the era of precise medicine. Various pre-targeting systems have been reported to address limitations associated with traditional immuno-PET. However, the application of these mono-receptor based pre-targeting (MRPT) strategies is limited to non-internalizable antibodies, and the tumor uptake is usually much lower than that in the corresponding immuno-PET. To circumvent these limitations, we develop the first Dual-Receptor Pre-Targeting (DRPT) system through entrapping the tumor-receptor-specific radioligand by the pre-administered antibody. Besides the similar ligation pathway happens in MRPT, incorporation of a tumor-receptor-specific peptide into the radioligand in DRPT enhances both concentration and retention of the radioligand on tumor, promoting its ligation with pre-administered mAb on cell-surface and/or internalized into tumor-cells. In this study, Cu based DRPT shows superior performance over corresponding MRPT and immuno-PET using internalizable antibodies. Besides, the compatibility of DRPT with short-lived and generator-produced Ga is demonstrated, leveraging its advantage in reducing radio-dose exposure. Furthermore, the feasibility of reducing the amount of the pre-administered antibody is confirmed, indicating the cost saving potential of DRPT. In summary, synergizing advantages of dual-receptor targeting and pre-targeting, we expect that this DRPT strategy can become a breakthrough technology in the field of antibody-based molecular imaging.
在精准医学时代,正电子发射断层扫描(PET)成像已成为一种重要的诊断工具。据报道,各种预靶向系统可解决与传统免疫PET相关的局限性。然而,这些基于单受体的预靶向(MRPT)策略的应用仅限于不可内化抗体,且肿瘤摄取通常远低于相应的免疫PET。为了克服这些局限性,我们通过预先给予的抗体捕获肿瘤受体特异性放射性配体,开发了首个双受体预靶向(DRPT)系统。除了在MRPT中发生的类似连接途径外,在DRPT的放射性配体中掺入肿瘤受体特异性肽可增强放射性配体在肿瘤上的聚集和滞留,促进其与预先给予的单克隆抗体在细胞表面连接和/或内化进入肿瘤细胞。在本研究中,基于铜的DRPT相对于使用可内化抗体的相应MRPT和免疫PET表现出卓越性能。此外,还证明了DRPT与短寿命和发生器产生的镓的兼容性,利用了其在减少辐射剂量暴露方面的优势。此外,还证实了减少预先给予抗体量的可行性,表明DRPT具有成本节约潜力。总之,通过协同双受体靶向和预靶向的优势,我们期望这种DRPT策略能够成为基于抗体的分子成像领域的一项突破性技术。